Riedl et al described a sixfold increased risk of developing VTE in glioblastoma patients with high podoplanin expression levels compared to patients with low levels.69These patients also demonstrated low platelet counts and high D-dimer levels, presumably due to the consumption of platelets following podoplanin-induced platelet aggregation. The gene discussed is PDPN; the disease is glioblastoma.